Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cytokinetics

35.90
-0.7300-1.99%
Post-market: 35.55-0.3500-0.97%19:48 EDT
Volume:1.02M
Turnover:36.77M
Market Cap:4.29B
PE:-6.78
High:37.09
Open:36.95
Low:35.86
Close:36.63
Loading ...

Cytokinetics Reports Fourth Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire
·
28 Feb

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
27 Feb

Cytokinetics, Incorporated (CYTK): the Most Oversold Pharma Stock to Buy According to Analysts

Insider Monkey
·
24 Feb

20 stocks of companies expected to put up numbers to back investors' new 'growth mindset'

Dow Jones
·
18 Feb

Cytokinetics rumor highlighted in Betaville alert

TIPRANKS
·
15 Feb

Morgan Stanley Upgrades Cytokinetics to Overweight From Equalweight, Trims Price Target to $67 From $70

MT Newswires Live
·
13 Feb

Positive Outlook for Cytokinetics: Buy Rating Based on Aficamten’s Advantages and Upcoming Catalysts

TIPRANKS
·
13 Feb

Cytokinetics upgraded to Overweight from Equal Weight at Morgan Stanley

TIPRANKS
·
13 Feb

BRIEF-Cytokinetics Names Robert E. Landry To Board Of Directors

Reuters
·
11 Feb

Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), Insmed (INSM) and IQVIA Holdings (IQV)

TIPRANKS
·
11 Feb

Why Cytokinetics, Incorporated (CYTK) Is Among the Best Healthcare Stocks To Buy According to Analysts

Insider Monkey
·
08 Feb

Cytokinetics Initiated at Buy by Citigroup

Dow Jones
·
08 Feb

Citigroup Initiates Cytokinetics at Buy With $86 Price Target

MT Newswires Live
·
07 Feb

Optimistic Buy Rating for Cytokinetics Driven by Aficamten’s Market Potential and Undervalued Shares

TIPRANKS
·
07 Feb

JMP Securities Sticks to Their Buy Rating for Cytokinetics (CYTK)

TIPRANKS
·
07 Feb

Cytokinetics Price Target Maintained With a $72.00/Share by Needham

Dow Jones
·
07 Feb

Camzyos news has negative readthroughs for Cytokinetics, says BofA

TIPRANKS
·
07 Feb

Positive Outlook for Cytokinetics Amid Rising HCM Market Demand and Developments

TIPRANKS
·
07 Feb

Cytokinetics’ Aficamten Poised for Market Success Amid Competitive Dynamics and Expanding HCM Opportunities

TIPRANKS
·
06 Feb

Cytokinetics share weakness on updated Camzyos REMS overdone, says Truist

TIPRANKS
·
06 Feb